| Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer CH Koh, N Bhoo-Pathy, KL Ng, RS Jabir, GH Tan, MH See, S Jamaris, ... British journal of cancer 113 (1), 150-158, 2015 | 368 | 2015 |
| Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity RS Jabir, R Naidu, MABA Annuar, GF Ho, M Munisamy, J Stanslas Pharmacogenomics 13 (16), 1979-1988, 2012 | 56 | 2012 |
| A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects P Meganathan, RS Jabir, HG Fuang, N Bhoo-Pathy, RB Choudhury, ... Scientific reports 5 (1), 13550, 2015 | 25 | 2015 |
| Association of allelic interaction of single nucleotide polymorphisms of influx and efflux transporters genes with nonhematologic adverse events of docetaxel in breast cancer … RS Jabir, GF Ho, MABA Annuar, J Stanslas Clinical breast cancer 18 (5), e1173-e1179, 2018 | 5 | 2018 |
| Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients RS Jabir, GF Ho, MABA Annuar, J Stanslas Biomarkers 23 (2), 142-146, 2018 | 5 | 2018 |
| CAS: 528: DC% 2BC2MXht1elsrvK: Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. vol. 113 CH Koh, N Bhoo-Pathy, KL Ng, RS Jabir, GH Tan, MH See, S Jamaris, ... Br J Cancer, 150-158, 2015 | 5 | 2015 |
| Docetaxel-induced mucositis in breast cancer patients: Association with plasma alpha-1-acid glycoprotein level and SLCO1B3 genotype RS Jabir, GF Ho, MAA Anuar, J Stanslas Cancer Research 74 (19_Supplement), 5563-5563, 2014 | 2 | 2014 |
| Efficacy versus toxicity of docetaxel in Asian and Caucasian cancer patients from the pharmacogenomics perspectives: a review of the literature RS Jabir, R Naidu, M Azrif, J Stanslas The FASEB Journal 24, 964.15-964.15, 2010 | 1 | 2010 |
| PHARMACOGENETICS OF CYP450A, ABCB1, ABCC2, SLCO1B3 GENE POLYMORPHISMS AND PLASMA ALPHA-1-ACID GLYCOPROTEIN LEVEL ON NONHAEMATOLOGICAL ADVERSE EVENTS OF DOCETAXEL IN MALAYSIAN … RS JABIR | | 2015 |
| Vomiting in docetaxel chemotherapy: which to blame, dose or gene?(655.4) R Jabir, G Ho, MA Anuar, J Stanslas The FASEB Journal 28, 655.4, 2014 | | 2014 |
| Single nucleotide polymorphisms of ABCB1, SLCO1B3, and CYP3A5: Potential biomarkers of docetaxel adverse effects in Malaysian breast cancer patients. RS Jabir, GF Ho, MAA Annuar, J Stanslas MOLECULAR CANCER THERAPEUTICS 12 (11), 2013 | | 2013 |
| Abstract A210: Single nucleotide polymorphisms of ABCB1, SLCO1B3, and CYP3A5: Potential biomarkers of docetaxel adverse effects in Malaysian breast cancer patients. RS Jabir, GF Ho, MAA Annuar, J Stanslas Molecular Cancer Therapeutics 12 (11_Supplement), A210-A210, 2013 | | 2013 |
| ANTIANGIOGENIC THERAPY IN CANCER: PROMISES AND REALITIES RS Jabir, AA Toe, MAA Annuar, J Stanslas | | |
| ASSOCIATION OF SIDE EFFECTS AND SINGLE NUCLEOTIDE POLYMRPHISMS OF GENES INVOLVED IN METABOLISM AND TRANSPORT OF DOCETAXEL IN BREAST CANCER PATIENTS RS Jabir, HG Fuang, MA bin Ahmad Annuar, J Stanslas | | |
